BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1557650)

  • 1. Combination fluorouracil, folinic acid, and interferon alfa-2a: an active regimen in advanced pancreatic carcinoma.
    Knuth A; Bernhard H; Klein O; Meyer zum Büschenfelde KH
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):211-4. PubMed ID: 1557650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
    Bernhard H; Jäger-Arand E; Bernhard G; Heike M; Klein O; Riemann JF; Meyer zum Büschenfelde KH; Dippold W; Knuth A
    Br J Cancer; 1995 Jan; 71(1):102-5. PubMed ID: 7819023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
    Jäger E; Bernhard H; Klein O; Wächter B; Theiss F; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Ann Oncol; 1995 Feb; 6(2):153-6. PubMed ID: 7540418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
    Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
    Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a.
    Bernhard H; Klein O; Meyer zum Büschenfelde KH; Knuth A
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):204-7. PubMed ID: 1557648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
    Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
    Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):220-4. PubMed ID: 1557652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
    J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
    J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
    Kosmidis PA; Tsavaris N; Skarlos D; Theocharis D; Samantas E; Pavlidis N; Briassoulis E; Fountzilas G
    J Clin Oncol; 1996 Oct; 14(10):2682-7. PubMed ID: 8874327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
    J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
    Pazdur R; Ajani JJ; Abbruzzese JL; Belt RJ; Dakhil SR; Dubovsky D; Graham S; Pilat S; Winn R; Levin B
    Cancer; 1992 Oct; 70(8):2073-6. PubMed ID: 1394037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.